{"id":"infliximab-plus-methotrexate","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Infections (including serious/opportunistic)"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"1-3","effect":"Tuberculosis reactivation"},{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"2-5","effect":"Cytopenias (methotrexate-related)"}]},"_chembl":{"chemblId":"CHEMBL1201581","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infliximab is a chimeric monoclonal antibody that binds TNF-α, a key pro-inflammatory cytokine, preventing its interaction with TNF receptors and thereby reducing systemic inflammation. Methotrexate acts as a disease-modifying antirheumatic drug (DMARD) by inhibiting dihydrofolate reductase and nucleotide synthesis, suppressing T-cell proliferation and immune activation. The combination provides synergistic anti-inflammatory and immunosuppressive effects.","oneSentence":"Infliximab blocks tumor necrosis factor-alpha (TNF-α) to suppress inflammation, while methotrexate inhibits dihydrofolate reductase to reduce immune cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:03.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT03885037","phase":"","title":"Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Rheumatoid Arthritis)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-03-20","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT06381518","phase":"NA","title":"Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2024-03-12","conditions":"IBD, Infliximab, Crohn Disease","enrollment":38},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":"Psoriasis","enrollment":1121},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT05072782","phase":"PHASE4","title":"Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2021-12-21","conditions":"Crohn Disease","enrollment":360},{"nctId":"NCT03088293","phase":"PHASE3","title":"Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2020-06-11","conditions":"Idiopathic Refractory Scleritis","enrollment":""},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT05051137","phase":"","title":"Real-World Emulation of the SWEFOT Trial","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01-12","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT03707535","phase":"PHASE3","title":"To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-11-12","conditions":"Rheumatoid Arthritis","enrollment":270},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT04196920","phase":"","title":"Methotrexate-associated Anti-TNF Combination Therapy, the Neglected One !","status":"UNKNOWN","sponsor":"University Hospital, Montpellier","startDate":"2019-12-20","conditions":"Chronic Inflammatory Bowel Disease","enrollment":200},{"nctId":"NCT03478111","phase":"PHASE3","title":"CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-03-30","conditions":"Rheumatoid Arthritis","enrollment":390},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT02413047","phase":"NA","title":"Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator","status":"TERMINATED","sponsor":"Indiana University","startDate":"2015-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease","enrollment":3},{"nctId":"NCT04109300","phase":"NA","title":"Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2020-09-01","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":162},{"nctId":"NCT03775824","phase":"","title":"Faecal Analyses in Rheumatoid Arthritis Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-08-01","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT03553472","phase":"","title":"Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-01","conditions":"Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease","enrollment":97},{"nctId":"NCT02762838","phase":"PHASE3","title":"Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":426},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT02269358","phase":"PHASE4","title":"Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation","status":"COMPLETED","sponsor":"Prof. Arie Levine","startDate":"2015-07","conditions":"Crohn's Disease","enrollment":22},{"nctId":"NCT02242474","phase":"PHASE4","title":"Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":660},{"nctId":"NCT02222493","phase":"PHASE3","title":"A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08-26","conditions":"Rheumatoid Arthritis","enrollment":650},{"nctId":"NCT03352622","phase":"NA","title":"Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Universidad de Antioquia","startDate":"2017-10-17","conditions":"Pharmacological Action","enrollment":372},{"nctId":"NCT02293681","phase":"","title":"An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-10","conditions":"Spondylitis, Ankylosing","enrollment":76},{"nctId":"NCT01936181","phase":"PHASE3","title":"A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2013-08","conditions":"Rheumatoid Arthritis","enrollment":584},{"nctId":"NCT01571219","phase":"PHASE3","title":"An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1","status":"COMPLETED","sponsor":"Celltrion","startDate":"2012-03","conditions":"Rheumatoid Arthritis","enrollment":302},{"nctId":"NCT00251641","phase":"PHASE3","title":"The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09-01","conditions":"Psoriasis","enrollment":868},{"nctId":"NCT00732875","phase":"PHASE3","title":"A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"Arthritis, Rheumatoid","enrollment":92},{"nctId":"NCT00833053","phase":"PHASE3","title":"Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Psoriasis","enrollment":39},{"nctId":"NCT00521924","phase":"PHASE3","title":"Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":8},{"nctId":"NCT00367237","phase":"PHASE3","title":"Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Arthritis, Psoriatic","enrollment":115},{"nctId":"NCT00794898","phase":"PHASE4","title":"Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-07-01","conditions":"Arthritis, Rheumatoid","enrollment":19},{"nctId":"NCT00202852","phase":"PHASE3","title":"A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06-01","conditions":"Arthritis, Rheumatoid","enrollment":143},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01850121","phase":"","title":"Remicade in the Treatment of Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2003-01","conditions":"Ankylosing Spondylitis","enrollment":19},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT02683564","phase":"PHASE3","title":"BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study","status":"UNKNOWN","sponsor":"Epirus Biopharmaceuticals (Switzerland) GmbH","startDate":"2016-02","conditions":"Rheumatoid Arthritis","enrollment":548},{"nctId":"NCT01783015","phase":"PHASE4","title":"Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00254982","phase":"PHASE3","title":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Psoriasis","enrollment":593},{"nctId":"NCT00748826","phase":"","title":"Remicade Safety Line (Study P03236)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-08","conditions":"Arthritis, Rheumatoid","enrollment":576},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT00462072","phase":"PHASE4","title":"Centocor Microarray Study of Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2007-03","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis","enrollment":31},{"nctId":"NCT00908089","phase":"PHASE4","title":"TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431},{"nctId":"NCT02376478","phase":"","title":"On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-12","conditions":"Psoriasis, Inflammatory Bowel Diseases","enrollment":222},{"nctId":"NCT00269867","phase":"PHASE3","title":"Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1997-03","conditions":"Rheumatoid Arthritis","enrollment":428},{"nctId":"NCT00132899","phase":"PHASE3","title":"COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)","status":"COMPLETED","sponsor":"University of Western Ontario, Canada","startDate":"2005-12","conditions":"Crohn's Disease","enrollment":128},{"nctId":"NCT00760669","phase":"","title":"An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-05","conditions":"Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis","enrollment":1061},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310},{"nctId":"NCT00896168","phase":"PHASE4","title":"An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2007-06","conditions":"Arthritis, Rheumatoid","enrollment":234},{"nctId":"NCT01915537","phase":"NA","title":"Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients","status":"UNKNOWN","sponsor":"Zhang, Xiao, M.D.","startDate":"2013-08","conditions":"Rheumatoid Arthritis（RA）","enrollment":170},{"nctId":"NCT00213564","phase":"","title":"Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2003-04","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01567358","phase":"PHASE1","title":"Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Nichi-Iko Pharmaceutical Co., Ltd.","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":14},{"nctId":"NCT01299545","phase":"","title":"Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":123},{"nctId":"NCT00207714","phase":"PHASE2","title":"An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2003-11","conditions":"Rheumatoid Arthritis","enrollment":172},{"nctId":"NCT00901550","phase":"NA","title":"The Chinese University of Hong Kong Early Arthritis Study","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00432432","phase":"PHASE4","title":"Combination Methotrexate and Infliximab","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2005-02","conditions":"Ankylosing Spondylitis","enrollment":38},{"nctId":"NCT00036387","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"","conditions":"Arthritis, Rheumatoid","enrollment":347},{"nctId":"NCT00236028","phase":"PHASE3","title":"A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":607},{"nctId":"NCT00246064","phase":"PHASE4","title":"The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol","status":"COMPLETED","sponsor":"Centocor Ortho Biotech Services, L.L.C.","startDate":"2001-12","conditions":"Arthritis, Rheumatoid","enrollment":210},{"nctId":"NCT00036374","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2001-10","conditions":"Rheumatoid Arthritis, Juvenile","enrollment":123},{"nctId":"NCT00716248","phase":"PHASE4","title":"Bucillamine Study of Holding Remission After Infliximab Dose-off","status":"UNKNOWN","sponsor":"Saitama Medical University","startDate":"2007-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT00764725","phase":"PHASE4","title":"Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT00554710","phase":"PHASE4","title":"Top Down Versus Step Up Strategies in Crohn's Disease","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2001-05","conditions":"Crohn's Disease","enrollment":129},{"nctId":"NCT00396747","phase":"PHASE4","title":"A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study","status":"COMPLETED","sponsor":"Université Catholique de Louvain","startDate":"2003-06","conditions":"Rheumatoid Arthritis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":81,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IFX: Remicade, MTX: Trexan or Methotrexate"],"phase":"phase_3","status":"active","brandName":"Infliximab plus methotrexate","genericName":"Infliximab plus methotrexate","companyName":"Helsinki University Central Hospital","companyId":"helsinki-university-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infliximab, a TNF-alpha inhibitor antibody, is used in combination with methotrexate to treat conditions such as Rheumatoid Arthritis, Arthritis, and Ulcerative Colitis. This combination targets the tumor necrosis factor, a protein involved in inflammation, to help manage these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}